Abstract: Novel cytosine-, thymine- and uracil-DNA glycosylases, subcellular localization peptides, nucleic acid molecules containing the same, methods of identifying such enzymes and their use in various methods including mutagenesis, cell killing and DNA sequencing and modification, are described.
Type:
Grant
Filed:
March 3, 1999
Date of Patent:
March 30, 2004
Inventors:
Hans E. Krokan, Geir Slupphaug, Bodil Kavli, John A. Tainer, Clifford D. Mol
Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the drug-metabolizing enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the drug-metabolizing enzyme peptides, and methods of identifying modulators of the drug-metabolizing enzyme peptides.
Type:
Grant
Filed:
February 1, 2002
Date of Patent:
March 30, 2004
Assignee:
Applera Corporation
Inventors:
Marion Webster, Ming-Hui Wei, Valentina Di Francesco, Ellen M. Beasley
Abstract: This invention comprises novel Rapamycin-FKBP12 binding proteins of mammalian origin for identification, design and synthesis of immunomodulatory, anti-restenosis or anti-tumor agents, as well as fragments of the proteins and the DNA, cDNA, antisense RNA and DNA segments corresponding to the proteins. This invention also comprises methods for isolating the proteins and therapeutic uses related to the proteins.
Type:
Grant
Filed:
September 13, 2001
Date of Patent:
March 30, 2004
Assignee:
Wyeth
Inventors:
Thomas J. Caggiano, Yanqiu Chen, Amedeo A. Failli, Katherine L. Molnar-Kimber, Koji Nakanishi
Abstract: DNA sequences obtained from S. clavuligerus ATCC 27064, recombinant vectors incorporating such sequences and hosts transformed with such vectors are disclosed.
The DNA comprises one or more genes coding for one or more enzymes involved in the biosynthesis of penicillin and cephalosporin &bgr;-lactams and such enzymes are expressed by hosts into which the recombinant vectors are transformed.
The DNA and the enzymes encoded thereby have utility in the preparation of penicillins and cephalosporins, both known and novel, possessing pharmacological, especially antimicrobial, activity.
Type:
Grant
Filed:
January 10, 2000
Date of Patent:
March 23, 2004
Assignee:
Beecham Group p.l.c.
Inventors:
Martin Karl Rossel Burnham, Ian David Normansell, John Edward Hodgson
Abstract: In one aspect, the present invention provides isolated nucleic acid molecules that each: (a) encode an aryl propenal double bond reductase; and (b) hybridize to a nucleic acid molecule consisting of the complement of the nucleic acid sequence set forth in SEQ ID NO:1 under defined conditions. The present invention also provides isolated aryl propenal double bond reductases. In other aspects, the present invention provides methods of enhancing or inhibiting the expression of aryl propenal double bond reductases in a plant.
Type:
Grant
Filed:
March 27, 2001
Date of Patent:
March 9, 2004
Assignee:
Washington State University Research Foundation
Inventors:
Hiroyuki Kasahara, Laurence B. Davin, Norman G. Lewis
Abstract: The present invention provides nucleotide sequences from Coryneform bacteria which code for the MtrA and/or MtrB proteins and processes for the fermentative preparation of amino acids using bacteria in which the mtrA and/or mtrB genes are attenuated.
Type:
Grant
Filed:
November 23, 2001
Date of Patent:
March 9, 2004
Assignee:
Degussa AG
Inventors:
Brigitte Bathe, Natalie Schischka, Michael Bott, Steffen Schaffer
Abstract: The invention provides a genetically modified Cyanobacteria having a construct comprising DNA fragments encoding pyruvate decarboxylase (pdc) and alcohol dehydrogenase (adh) enzymes obtained from the Zymomonas mobilis plasmid pLOI295. The Cyanobacteria are capable of producing ethanol in recoverable quantities of at least 1.7 &mgr;mol ethanol per mg of chlorophyll per hour.
Type:
Grant
Filed:
May 21, 2001
Date of Patent:
March 2, 2004
Assignee:
Enol Energy Inc.
Inventors:
Robert Paul Woods, John Robert Coleman, Ming De Deng
Abstract: The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
Type:
Grant
Filed:
April 25, 2000
Date of Patent:
March 2, 2004
Assignee:
Samyang Genex Corporation
Inventors:
Jeong Hyun Kim, Min Hyung Kang, Jae Hyun Lee, Se Ho Park, Joo Won Lee, Seung Suh Hong, Hyun Soo Lee
Abstract: The present invention relates to polynucleotides corresponding to the nadA gene and which encode the quinolinate synthetase A protein, methods of producing nicotinic acid or nicotinic acid derivatives, and methods of screening for polynucleotides which encode proteins having quinolinate synthetase A activity.
Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the phospholipase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the phospholipase peptides, and methods of identifying modulators of the phospholipase peptides.
Type:
Grant
Filed:
March 14, 2002
Date of Patent:
February 10, 2004
Assignee:
Applera Corporation
Inventors:
Karl Guegler, Ellen M. Beasley, Karen A. Ketchum, Valentina Di Francesco
Abstract: The invention relates to polynucleotides corresponding to the ccpA2 gene and which encode a CcpA2 catabolite control protein, methods of producing L-amino acids, and methods of screening for polynucleotides which encode proteins having CcpA2 catabolite control activity.
Type:
Grant
Filed:
August 27, 2001
Date of Patent:
February 10, 2004
Assignee:
Degussa AG
Inventors:
Bettina Moeckel, Caroline Kreutzer, Thomas Hermann, Mike Garwick, Achim Marx, Walter Pfefferle
Abstract: BTL.010 is a novel human serine proteinase inhibitor of the Kunitz family that exhibits greater potency towards neutral serine proteinases, particularly leukocyte elastase and proteinase 3 than towards trypsin-like proteinases. BTL.010, or variants thereof, may be employed as therapeutics in diseases such as emphysema, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, cystic fibrosis, rheumatoid arthritis, organ failure, and glomerulonephritis in which uncontrolled proteolysis due to neutral serine proteinase activity results in tissue damage.
Type:
Grant
Filed:
May 12, 2000
Date of Patent:
February 10, 2004
Assignee:
Bayer Pharmaceuticals Corporation
Inventors:
Christopher Davies, Dadong Chen, Steve Roczniak
Abstract: Disclosed is a method of using bifunctional binding molecules, such as two linked VH-VL single chain binding molecules, to recruit a therapeutic agent to a solid tissue site. The therapeutic agent is administered separately from the binding molecules and following the administration of a remover substance which aids in clearing free binding molecules in the circulation. In the preferred mode of the invention, the binding molecules have one specificity for antigens at the target site and one for the therapeutic agent. The binding molecules are administered and allowed time to approach a maximum concentration in the extravascular space. A remover substance, preferably a liposome conjugated with antibodies which are reactive with an antigenic epitope on the binding molecules, is then administered to remove excess binding molecules from the circulation and the extravascular space.
Abstract: Through function complementation of E. coli auxotrophs, the ultimate and pentultimate enzymes of the spinach riboflavin biosynthetic pathway have been cloned, namely, lumazine synthase (LS) and riboflavin synthase (RS). This invention relates to the isolation of nucleic acid fragments from plants or fungi that encode LS protein. The invention also relates to the isolation of nucleic acid fragments from plants or fungi that encode RS protein. In addition, the invention also relates to the construction of chimeric genes encoding all of a portion of LS, in sense or antisense orientation, wherein the expression of the chimeric gene results in production of altered levels of plant LS in a transformed host cell. Furthermore, the invention also relates to the construction of chimeric genes encoding all of a portion of RS, in sense or antisense orientation, wherein the expression of the chimeric gene results in production of altered levels of plant or fungal RS in a transformed host cell.
Type:
Grant
Filed:
June 5, 2001
Date of Patent:
January 27, 2004
Assignee:
E. I. du Pont de Nemours and Company
Inventors:
Paul Veikko Viitanen, Douglas Brian Jordan, Karen Onley Bacot
Abstract: Compositions and methods are described that are useful to assay for compouds that affect PKB kinase activity which have medical applications for the diagnosis and treatment of disease.
Type:
Grant
Filed:
September 17, 1998
Date of Patent:
January 27, 2004
Assignee:
Onyx Pharmaceuticals, Inc.
Inventors:
Len Stephens, Philip Hawkins, David Stokoe
Abstract: The present invention relates to enzymes produced by mutating the genes for a number of subtilases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved stability and/or improved wash performance in any detergent in comparison to their wild type parent enzymes. The enzymes are well-suited for use in any detergent and for some in especially liquid or solid shaped detergent compositions.
Type:
Grant
Filed:
June 5, 2000
Date of Patent:
January 27, 2004
Assignees:
Novozymes A/S, Unilever
Inventors:
Laurens Nicolaas Sierkstra, Jan Klugkist, Peter Markvardsen, Claus von der Osten, Peter Bauditz
Abstract: This invention relates to an isolated nucleic acid fragment encoding a polyphenol oxidase enzyme. The invention also relates to the construction of a chimeric gene encoding all or a portion of the polyphenol oxidase enzyme, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the polyphenol oxidase enzyme in a transformed host cell.
Type:
Grant
Filed:
July 16, 2001
Date of Patent:
January 20, 2004
Assignee:
E. I. du Pont de Nemours and Company
Inventors:
Rebecca E. Cahoon, Saverio Carl Falco, Anthony J. Kinney, Guo-Hua Miao
Abstract: The present invention relates to the nucleic acid molecules encoding an STE20-related family of novel protein kinases, ZC1, ZC2, ZC3, ZC4, STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, KHS2, SULU1, SULU3, GEK2, PAK4 and PAK5, segments and domains thereof, as well as various methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Mammalian nucleic acid molecules encoding these kinases are particularly disclosed, and more specifically human sources of these nucleic acids are disclosed.
Type:
Grant
Filed:
April 13, 1999
Date of Patent:
January 20, 2004
Assignee:
Sugen, Inc.
Inventors:
Gregory Plowman, Ricardo Martinez, David Whyte
Abstract: The present invention relates to polynucleotides corresponding to the plsC gene and which encode 1-acyl-SN-glycerol-3-phosphate acyltransferase, methods of producing L-amino acids, and methods of screening for polynucleotides which encode proteins having 1-acyl-SN-glycerol-3-phosphate acyltransferase activity.